AMGN Stock Recent News
AMGN LATEST HEADLINES
In the closing of the recent trading day, Amgen (AMGN) stood at $335.61, denoting a -0.52% change from the preceding trading day.
THOUSAND OAKS, Calif. , Sept. 23, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:30 p.m.
Many healthcare companies are working hard now on developing the next big weight loss drug. Industry veteran Amgen has an exciting treatment that may not require frequent injections.
CNBC's Jim Cramer on Thursday reviewed stocks that have historically performed well just after the Federal Reserve embarks on a cutting cycle and chose his favorites. Using data compiled by CNBC Pro, Cramer discussed the top 10 stocks with the median best performance during three months after an initial cut over the past 40 years.
Amgen (AMGN) reachead $332.80 at the closing of the latest trading day, reflecting a -0.73% change compared to its last close.
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen (AMGN) closed the most recent trading day at $335.26, moving +0.85% from the previous trading session.
Eli Lilly and Novo Nordisk have been top stocks for investors who are bullish on the weight loss market. However, fellow biotech Amgen could possess more upside given its more modest valuation.
Amgen (AMGN) reachead $328.93 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.
Tango Therapeutics, Inc. offers high-risk, high-reward exposure to PRMT5-inhibitor drugs, with two candidates, TNG908 and TNG462, targeting MTAP-deleted cancers, a substantial market opportunity. TNGX stock volatility is influenced by competitors' PRMT5 data, with recent fluctuations driven by Amgen and Mirati's clinical results. Tango's financial stability is supported by >$300M in cash, a Gilead partnership, and a funding runway until 2027, covering key clinical readouts.